QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Competitors

$0.53
-0.02 (-3.66%)
(As of 09/21/2023 ET)
Compare
Today's Range
$0.50
$0.58
50-Day Range
$0.31
$1.75
52-Week Range
$0.29
$6.37
Volume
103,854 shs
Average Volume
565,309 shs
Market Capitalization
$12.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

IMPL vs. TFFP, VYNE, AIMD, RVLP, VCNX, NRBO, AKTX, BCEL, AEZS, and KTTA

Should you be buying Impel Pharmaceuticals stock or one of its competitors? The main competitors of Impel Pharmaceuticals include TFF Pharmaceuticals (TFFP), VYNE Therapeutics (VYNE), Ainos (AIMD), RVL Pharmaceuticals (RVLP), Vaccinex (VCNX), NeuroBo Pharmaceuticals (NRBO), Akari Therapeutics (AKTX), Atreca (BCEL), Aeterna Zentaris (AEZS), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.

Impel Pharmaceuticals vs.

Impel Pharmaceuticals (NASDAQ:IMPL) and TFF Pharmaceuticals (NASDAQ:TFFP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.

TFF Pharmaceuticals has lower revenue, but higher earnings than Impel Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Impel Pharmaceuticals$12.65M0.99-$106.31M-$3.86-0.14
TFF Pharmaceuticals$500K25.30-$31.77MN/AN/A

TFF Pharmaceuticals received 56 more outperform votes than Impel Pharmaceuticals when rated by MarketBeat users. Likewise, 67.35% of users gave TFF Pharmaceuticals an outperform vote while only 52.63% of users gave Impel Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Impel PharmaceuticalsOutperform Votes
10
52.63%
Underperform Votes
9
47.37%
TFF PharmaceuticalsOutperform Votes
66
67.35%
Underperform Votes
32
32.65%

Impel Pharmaceuticals has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, TFF Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Impel Pharmaceuticals currently has a consensus target price of $19.67, suggesting a potential upside of 3,638.91%. TFF Pharmaceuticals has a consensus target price of $5.50, suggesting a potential upside of 1,475.93%. Given Impel Pharmaceuticals' higher probable upside, analysts clearly believe Impel Pharmaceuticals is more favorable than TFF Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Impel Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
TFF Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Impel Pharmaceuticals has a net margin of -480.74% compared to TFF Pharmaceuticals' net margin of -3,403.80%. Impel Pharmaceuticals' return on equity of 0.00% beat TFF Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Impel Pharmaceuticals-480.74% N/A -120.77%
TFF Pharmaceuticals -3,403.80%-153.28%-140.39%

In the previous week, Impel Pharmaceuticals had 1 more articles in the media than TFF Pharmaceuticals. MarketBeat recorded 1 mentions for Impel Pharmaceuticals and 0 mentions for TFF Pharmaceuticals. Impel Pharmaceuticals' average media sentiment score of 0.00 equaled TFF Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Impel Pharmaceuticals Neutral
TFF Pharmaceuticals Neutral

73.9% of Impel Pharmaceuticals shares are held by institutional investors. Comparatively, 17.7% of TFF Pharmaceuticals shares are held by institutional investors. 6.2% of Impel Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of TFF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Impel Pharmaceuticals beats TFF Pharmaceuticals on 8 of the 15 factors compared between the two stocks.


Get Impel Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMPL and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMPL vs. The Competition

MetricImpel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.49M$5.14B$4.32B$6.27B
Dividend YieldN/A2.64%2.40%5.88%
P/E Ratio-0.147.13137.6313.70
Price / Sales0.99156.212,812.3268.98
Price / CashN/A20.7387.40101.50
Price / Book-0.283.723.764.72
Net Income-$106.31M$178.51M$121.73M$185.68M
7 Day Performance-22.53%-5.08%-2.09%-3.32%
1 Month Performance51.59%-5.93%-0.81%-4.41%
1 Year Performance-91.45%2.63%5.40%1.33%

Impel Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TFFP
TFF Pharmaceuticals
2.0247 of 5 stars
$0.37
+2.8%
$5.50
+1,404.4%
-93.7%$13.25M$500,000.000.0015Gap Up
VYNE
VYNE Therapeutics
2.2155 of 5 stars
$4.08
-1.0%
$18.50
+353.4%
-23.8%$13.38M$407,000.00-0.3712Positive News
AIMD
Ainos
0 of 5 stars
$0.66
+3.1%
N/AN/A$13.39M$2.87M-0.7643Gap Up
RVLP
RVL Pharmaceuticals
1.8457 of 5 stars
$0.11
+9.6%
$2.50
+2,079.6%
-95.9%$12.78M$36.92M-0.16125News Coverage
Gap Down
High Trading Volume
VCNX
Vaccinex
0 of 5 stars
$0.21
flat
N/A-76.8%$13.52M$650,000.00-0.4738Gap Down
NRBO
NeuroBo Pharmaceuticals
0 of 5 stars
$0.46
+2.2%
N/A-97.6%$12.64MN/A0.002Gap Down
AKTX
Akari Therapeutics
2.2015 of 5 stars
$3.68
+4.8%
$55.00
+1,394.6%
-71.9%$13.69MN/A-0.5315Upcoming Earnings
Analyst Report
News Coverage
Gap Down
BCEL
Atreca
1.8083 of 5 stars
$0.35
+2.9%
$10.75
+2,971.4%
-82.3%$13.76MN/A-0.1690News Coverage
AEZS
Aeterna Zentaris
1.6389 of 5 stars
$2.55
-3.8%
$28.00
+998.0%
-39.2%$12.38M$8.72M-0.5511Analyst Report
KTTA
Pasithea Therapeutics
2.2236 of 5 stars
$0.54
+1.9%
$2.00
+273.0%
-60.8%$14.02M$486,559.000.0015News Coverage
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:IMPL) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -